logo

Acelrx Pharmaceuticals Inc. (ACRX)



Trade ACRX now with
  Date
  Headline
8/30/2021 8:35:15 AM AcelRx: Results Announced During Presentation On Effect Of Sufentanil Sublingual Tablet On Outpatient Plastic Surgery
8/16/2021 4:04:00 PM AcelRx Pharma Q2 Loss/share $0.08, Same As Last Year
7/14/2021 8:38:09 AM AcelRx Reaches Deal For DZUVEO In Europe And In-licensing Deal For Two Products In U.S.
6/17/2021 8:40:32 AM AcelRx Enters Agreement With FDA Addressing Warning Letter Received For DSUVIA Promotional Materials
5/26/2021 9:49:32 AM AcelRx Announces Presentation On Use Of DSUVIA For Plastic Surgery Procedures Selected For "Best Papers" Session
5/20/2021 8:50:50 AM AcelRx Announces Investigator-initiated Study To Be Conducted At Tampa General Hospital To Evaluate DSUVIA
5/17/2021 4:05:58 PM AcelRx Pharma Q1 Loss/share $0.08 Vs. Loss $0.20 Year Ago
5/13/2021 9:49:14 AM AcelRx : Study Of DSUVIA Showing Reduction In Postoperative Opioids And Better OBAS Scores Compared To Control Group
3/31/2021 8:32:24 AM AcelRx Appoints Marina Bozilenko As An Independent Member Of Board
3/25/2021 8:42:22 AM AcelRx Announces Publication Of Pooled Analysis Of Phase 3 Data On Use Of DSUVIA For Acute Pain Management
3/15/2021 5:21:25 PM AcelRx Pharmaceuticals Q4 Loss/share $0.10 Vs. Loss $0.18 Year Ago
1/20/2021 9:03:42 AM AcelRx Prices $27.5 Mln Public Offering Of Common Stock